Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

36.13 +0.06 (+0.17%)
Official Closing Price Updated: 7:00 PM EST, Feb 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
37 38 Next >
4 Undervalued Biotech Stocks to Add to Your Buy List
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
As Evolving Pandemic Response, Officials Shift To Personal Choice On COVID-19 Boosters, Masks: WSJ
In the latest phase of the COVID-19 pandemic, federal and local officials are leaving it up to people to assess if they need booster shots, whether to wear a mask and how long to isolate after a... 
Via Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting... 
Via Benzinga
Why Is Sierra Oncology (SRRA) Stock Up Today?
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. 
Via InvestorPlace
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029
Via Benzinga
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
Via Investor Brand Network
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
Via Investor Brand Network
Sierra Oncology Stock Is Soaring: Here's Why
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in... 
Via Benzinga
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares
GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying. 
Via Investor's Business Daily
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
Via Benzinga
Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here
Via Benzinga
CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Watch For Continued Gains In Shares Of GlaxoSmithKline PLC (GSK)
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Highly Rated GlaxoSmithKline Eyes Breakout After Racking Up Series Of Wins
The move comes after the FDA shut down its Vir-partnered Covid antibody, however. 
Via Investor's Business Daily
What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates?
Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier. 
Via Benzinga
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
From GSK
Via Business Wire
Good and Bad stock news
Microsoft is down because of an FTC investigation of its possible anti-competitive moves. 
Via Talk Markets
EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine
Via Benzinga
Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility
Vir Biotechnology remains under pressure despite its looming addition to a new index. 
Via Investor's Business Daily
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Omicron BA.2 Variant Represents More Than 50% COVID-19 Cases, Says CDC Estimates: WSJ
According to the Centers for Disease Control and Prevention estimates, the omicron BA.2 variant represents approximately 55% of new COVID-19 cases in the U.S., as signs suggest infections are edging... 
Via Benzinga
FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV
Via Benzinga
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country 
Via Benzinga
Monday Markets News
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
Via Benzinga
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. 
Via InvestorPlace
Drug makers, Scientists Working For Long COVID Treatments: Reuters
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,  
Via Benzinga
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher. 
Via Investor's Business Daily
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.